With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
It is the first branded generic alternative to Fostair 100/6 pMDI
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
The facility sets a new benchmark in respiratory diagnostics
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
